We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+9.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.52B
AUM Growth
+$387M
(+18%)
Cap. Flow
+$192M
Cap. Flow
% of AUM
7.6%
Top 10 Holdings %
Top 10 Hldgs %
45.8%
Holding
129
New
32
Increased
30
Reduced
16
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$33.4M |
| 2 |
AbbVie
ABBV
|
+$31.2M |
| 3 |
AGN
Allergan plc
AGN
|
+$24M |
| 4 |
Baxter International
BAX
|
+$22.3M |
| 5 |
Gilead Sciences
GILD
|
+$20.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$59.8M |
| 2 |
AGN
Allergan Inc
AGN
|
+$48.5M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$28.5M |
| 4 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
+$22.4M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$17.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.13% |
| 2 | Real Estate | 3.95% |
| 3 | Financials | 1.4% |
| 4 | Industrials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $230M | 9.11% |
1,994,834
| – | – |
|
|
2
Gilead Sciences
GILD
$163B
| $224M | 8.86% |
2,279,731
+199,000
| +10% | +$20.2M |
|
3
Biogen
BIIB
$30.7B
| $143M | 5.68% |
339,483
+12,200
| +4% | +$4.81M |
|
|
AGN
4
DELISTED
Allergan plc
AGN
| $108M | 4.27% |
361,686
+84,055
| +30% | +$24M |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
| $87M | 3.45% |
502,305
+25,200
| +5% | +$4.56M |
|
6
Incyte
INCY
$24.9B
| $85.8M | 3.4% |
936,461
| – | – |
|
7
Regeneron Pharmaceuticals
REGN
$77.4B
| $84.5M | 3.35% |
187,166
-11,200
| -6% | -$4.75M |
|
8
BioMarin Pharmaceuticals
BMRN
$11.7B
| $66.7M | 2.64% |
534,977
-35,050
| -6% | -$3.71M |
|
|
9
AbbVie
ABBV
$455B
| $65M | 2.58% |
1,110,614
+516,395
| +87% | +$31.2M |
|
|
10
Teva Pharmaceuticals
TEVA
$41.2B
| $62.1M | 2.46% |
997,594
+574,000
| +136% | +$33.4M |
|
11
Viatris
VTRS
$20.7B
| $60M | 2.38% |
1,010,105
| – | – |
|
12
Pfizer
PFE
$142B
| $57M | 2.26% |
1,726,706
| – | – |
|
13
Amgen
AMGN
$209B
| $56.2M | 2.23% |
351,779
-28,500
| -7% | -$4.49M |
|
|
14
Vertex Pharmaceuticals
VRTX
$122B
| $54.8M | 2.17% |
464,244
-237,700
| -34% | -$28.5M |
|
15
Johnson & Johnson
JNJ
$617B
| $43.7M | 1.73% |
434,612
+107,400
| +33% | +$10.9M |
|
|
16
CALL
Gilead Sciences
GILD
$163B
| $42.2M | 1.67% |
430,100
+429,139
| +44,655% | +$43.6M |
|
|
AKRX
17
DELISTED
Akorn Inc
AKRX
| $40.4M | 1.6% |
849,482
| – | – |
|
18
Alkermes
ALKS
$8.39B
| $35.9M | 1.42% |
588,470
+151,500
| +35% | +$10.4M |
|
|
AET
19
DELISTED
Aetna Inc
AET
| $35.4M | 1.4% |
331,931
| – | – |
|
20
Bristol-Myers Squibb
BMY
$132B
| $34.5M | 1.37% |
535,240
| – | – |
|
|
CTRX
21
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| $25.8M | 1.02% |
433,600
| – | – |
|
22
Illumina
ILMN
$31B
| $24.7M | 0.98% |
136,972
+30,223
| +28% | +$5.69M |
|
23
Molina Healthcare
MOH
$10.2B
| $23.4M | 0.93% |
347,901
| – | – |
|
|
ACOR
24
DELISTED
Acorda Therapeutics
ACOR
| $22.7M | 0.9% |
5,674
+3,398
| +149% | +$15.6M |
|
|
ENDP
25
DELISTED
Endo International plc
ENDP
| $22.6M | 0.89% |
251,773
| – | – |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q1 2015 Portfolio in Review
As of Q1 2015, Tekla Capital Management held 129 positions worth $2.52B, up 18% from $2.14B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Tekla Capital Management deployed $192M of net new capital in Q1 2015, opening 32 new positions and adding to 30 existing holdings. Its largest new stake was Baxter International: 588,384 shares worth $21.9M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $28.5M trimmed.
- Tekla Capital Management's largest Q1 2015 buy was Baxter International: 588,384 shares worth $21.9M.
- Tekla Capital Management added most to Teva Pharmaceuticals in Q1 2015, an estimated $33.4M increase.
- Tekla Capital Management's biggest Q1 2015 reduction was Vertex Pharmaceuticals, cutting an estimated $28.5M.
- Tekla Capital Management fully exited Shire pic in Q1 2015, selling an estimated $59.8M.
- Tekla Capital Management's ten largest holdings make up 46% of its $2.52B portfolio in Q1 2015.
- Tekla Capital Management opened 32 new positions and closed 13 in Q1 2015.
- Tekla Capital Management's portfolio value rose 18% quarter-over-quarter to $2.52B.
Based on Tekla Capital Management's 13F filing for Q1 2015, filed 6 May 2015.